Biological events that contribute to the pathogenesis of myelodysplastic
syndromes/neoplasms (MDS) are becoming increasingly characterized and are being …

Myeloid malignancies are devastating hematologic cancers with limited therapeutic options.
Inflammation is emerging as a novel driver of myeloid malignancy, with important …

Ovarian cancer is resistant to immune checkpoint blockade (ICB) treatment. Combination of
targeted therapy and immunotherapy is a promising strategy for ovarian cancer treatment …

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic
stem cell disorders characterized by myeloid dysplasia, peripheral blood cytopenias, and …

Dysregulation of the innate immune system and inflammatory-related pathways has been
implicated in hematopoietic defects in the bone marrow microenvironment and associated …

Dysregulation of innate immune signaling is a hallmark of hematologic malignancies.
Recent therapeutic efforts to subvert aberrant innate immune signaling in myelodysplastic …

Myelodysplastic neoplasm (MDS) is a hematopoietic stem cell disorder that may evolve into
acute myeloid leukemia. Fatal infection is among the most common cause of death in MDS …

Mutations of splicing factor genes (including SF3B1, SRSF2, U2AF1 and ZRSR2) occur in
more than half of all patients with myelodysplastic syndromes (MDS), a heterogeneous …

Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by
ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by …

Hematopoietic stem and progenitor cells (HSPCs) sustain lifelong hematopoiesis. Mutations
of pre-mRNA splicing machinery, especially splicing factor 3b, subunit 1 (SF3B1), are early …